Introduction
============

Prostate cancer is the second most common malignant tumor in men in Western countries, and the number of newly diagnosed prostate cancer patients is 129.4 per 100,000 men per year ^\[[@R1]\]^. Among various risk factors for prostate cancer, genetic factors, including race, family, and specific gene variants, might be associated with prostate cancer. Especially, among specific gene variants, mutations in *BRCA1* and *BRCA2* , Hereditary Prostate cancer gene 1 ( *HPC1* ), and *TMPRSS2-ERG* gene fusion are linked to prostate cancer ^\[[@R2]-[@R3]\]^.

Recently, several studies have reported that the genetic polymorphisms of several genes at 17q12, 17q24.3, and 8q24 are significantly associated with prostate cancer^\[[@R4]--[@R7]\]^. There is growing interest in the role of genetic polymorphism in the risk for prostate cancer according to genetic polymorphism in patients with prostate cancer.

Prostate stem cell antigen ( *PSCA* ) is a cell-membrane glycoprotein consisting of 123 amino acids and highly expressed in the prostate and bladder^\[[@R8],\ [@R9]\]^. Furthermore, *PSCA* is highly expressed in human prostate cancer, but has limited expression in normal tissues, which has become a potential target biomarker in prostate cancer. Interestingly, Joung *et al* . ^\[[@R10]\]^ have demonstrated that men with the rs1045531AA genotype of *PSCA* are at high risk of prostate cancer in genotype analysis. However, there have been few reports about the relationship between rs2294008 of *PSCA* and prostate cancer. Therefore, we evaluated the association between rs2294008 and the risk of prostate cancer.

Materials and methods
=====================

Study population
----------------

This study recruited data from 240 patients who underwent radical prostatectomy or palliative transurethral resection of the prostate (TURP) and were histologically confirmed to have adenocarcinoma of the prostate and 306 benign prostatic hyperplasia (BPH) patients for controls. Gleason scores (GS) were assigned to 12 specimens obtained from core transurethral biopsy, TURP, or radical prostatectomy. Tumor stage was estimated for specimens obtained from radical prostatectomy, and TNM 2002 stage was determined using computed tomography (CT), magnetic resonance imaging, or bone scanning.

Collection and analysis of the samples were approved by the Institutional Review Board of Chungbuk National University, and each subject provided written informed consent (IRB approval number: 2010-12-010).

Blood sampling, DNA extraction, and genotype assays of polymorphism
-------------------------------------------------------------------

From each patient, a 5 mL of blood sample of was collected with a 0.1 mL EDTA tube before the operation, frozen in liquid nitrogen, and stored at --80°C. Genomic DNA was extracted from human whole blood for genotyping using a genomic DNA purification kit (Promega, Madison, WI, USA) in accordance with the manufacturer\'s instructions.

*PSCA* genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The PCR primers for *PSCA* rs2294008 were 5′-AAACCCGCTG- GTGTTGACT-3′ (sense) and 5′-TCCCTTCCTCCTTCCTTCC-3′ (antisense). DNA (200 ng) was amplified in a total volume of 20 µL, containing 10 pmol of each primer, 0.5 U *Taq* polymerase, 2.5 mmol/L deoxyribonucleotide triphosphate, and 10xPCR buffer. PCR conditions were as follows: initial denaturation step at 95°C for 5 minutes and then 39 cycles of amplification were carried out at 95°C for 45 seconds, 50°C for 45 seconds, and 72°C for 60 seconds, with a final extension step at 72°C for 10 minutes. PCR products were digested overnight at 37°C with *Nla III* (New England BioLabs, Beverly, MA, USA) according to the manufacturer\'s instructions and then separated by electrophoresis on 3% agarose with ethidium bromide staining. PCR products were shown to be digested into 3 types of TT (98 and 158 bp), CT (98, 158, and 256 bp), and CC (256 bp) genotypes.

Statistical analysis
--------------------

Clinical variables, such as age, GS, PSA, stage, and metastasis, according to genetic polymorphism were compared by the Chi-square test. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using logistic regression models. Wild-type genotypes (CC) were considered baseline risk. Using the Hardy--Weinberg equilibrium test, the expected frequency of control genotypes was analyzed. Statistical analyses were performed by using Statistical Package for Social Sciences version 23.0 (IBM, Armonk, NY, USA). All tests were performed using 2-tailed analysis and a *P* value of 0.05 was considered statistically significant.

Results
=======

Baseline characteristics
------------------------

The mean age of 240 prostate cancer patients was 68.58±7.12 years, and that of 306 controls was 70.12±7.50 years. One hundred and fourteen (47.5%) patients had stage T2, 80 (33.3%) had stage T3, and 46 (19.2%) had stage T4 prostate cancer. The baseline characteristics of the patients are summarized in ***Table 1*** .

###### 

Baseline characteristics of the subjects

                           Control      Prostate cancer
  ------------------------ ------------ -----------------
  Number                   306          240
  Age, *n* (%)^†^          70.12±7.50   68.58±7.12
   70 years                136 (44.4)   132 (55.0)
  ≥70 years                170 (55.6)   108 (45.0)
  Gleason score, *n* (%)                
  ≤7                                    120 (50.0)
  8                                     72 (30.0)
  ≥9                                    48 (20.0)
  PSA (ng/mL), *n* (%)                  
   20                                   117 (48.7)
  ≥20, 50                               60 (25.0)
  ≥50                                   63 (26.3)
  Stage, *n* (%)                        
  T2                                    114 (47.5)
  T3                                    80 (33.3)
  T4                                    46 (19.2)
  Metastasis, *n* (%)                   
  non-metastasis                        196 (81.7)
  metastasis                            44 (18.3)

^†^Prostate cancer compared with controls, *P*  0.05.

Association between the risk of prostate cancer and ***PSCA*** (rs2294008)
--------------------------------------------------------------------------

***Table 2*** shows genotypes and allele frequencies for rs2294008 in prostate cancer patients and controls. For prostate cancer, the CC, CT, and TT genotypes were observed in 22.5%, 56.2%, and 21.3% of the patients, respectively, and for controls, 25.5%, 53.3%, and 21.2%, respectively. The genotype frequencies for rs2294008 followed the Hardy--Weinberg equilibrium ( *P* = 0.623). Compared with the CC genotype, the CT and TT genotypes were associated with insignificant risk of prostate cancer ( *P* = 0.627 and 0.397, respectively).

###### 

Association between the risk of prostate cancer and the ***PSCA*** gene rs2294008

       Control^†^   Prostate cancer^†^   OR (95% CI)           *P* value
  ---- ------------ -------------------- --------------------- -----------
  CC   78 (25.5)    54 (22.5)            1                     
  CT   163 (53.3)   135 (56.2)           0.882 (0.533-1.462)   0.627
  TT   65 (21.2)    51 (21.3)            0.836 (0.552-1.266)   0.397
  C    319 (52.1)   243 (50.6)           1                     
  T    293 (47.9)   237 (49.4)           0.942 (0.741-1.196)   0.632

^†^Genotype distribution and Hardy-Weinberg equilibrium ( *P* =0.623). OR: odds ratio; CI: confidence interval

Relationship between ***PSCA*** and clinicopathologic parameters in prostate cancer
-----------------------------------------------------------------------------------

As shown in ***Table 3*** , there was no significant difference in rs2294008 according to clinicopathologic parameters, such as age, GS, PSA, stage, and metastasis in prostate cancer ( *P* \>0.05 for each).

###### 

Relationship between ***PSCA*** (rs2294008) and clinicopathological parameters in prostate cancer

                                       PSCA                     
  ------------------------ ----------- ------------ ----------- -------
  Age, *n* (%)                                                  0.253
   70 years                35 (26.5)   71 (53.8)    26 (19.7)   
  ≥70 years                19 (17.6)   64 (59.3)    25 (23.1)   
  Gleason score, *n* (%)                                        0.633
  ≤7                       26 (21.7)   69 (57.5)    25 (20.8)   
  8                        20 (27.8)   36 (50.0)    16 (22.2)   
  ≥9                       8 (16.7)    30 (62.5)    10 (20.8)   
  PSA (ng/mL), *n* (%)                                          0.686
   20                      29 (24.8)   64 (54.7)    24 (20.5)   
  ≥20, 50                  11 (18.3)   33 (55.0)    16 (26.7)   
  ≥50                      14 (22.2)   38 (60.3)    11 (17.5)   
  Stage, *n* (%)                                                0.784
  T2                       28 (24.5)   63 (55.3)    23 (20.2)   
  T3                       15 (18.7)   45 (56.3)    20 (25.0)   
  T4                       11 (23.9)   27 (58.7)    8 (17.4)    
  Metastasis, *n* (%)                                           0.195
  non-metastasis           42 (21.4)   108 (55.1)   46 (23.5)   
  metastasis               12 (27.3)   27 (61.4)    5 (11.4)    

Stratified analysis of ***PSCA*** according to prostate cancer classification
-----------------------------------------------------------------------------

The association between *PSCA* and prostate cancer was further evaluated by stratified analysis of age, GS, PSA, pathologic stage, and metastasis. As shown in ***Table 4*** , age, GS, PSA, pathologic stage, and metastasis did not modify the association between *PSCA* and the risk of prostate cancer ( *P* \>0.05 for each).

###### 

Stratified analysis of the ***PSCA*** gene (rs2294008) according to prostate cancer classification

                           PSCA   Prostate cancer   OR (95% CI)           *P* value
  ------------------------ ------ ----------------- --------------------- -----------
  Age, *n* (%)                                                            
   70 years                CC     35 (26.5)         1                     
  ( *n* =132)              CT     71 (53.8)         1.047 (0.516-2.126)   0.899
                           TT     26 (19.7)         0.986 (0.558-1.742)   0.986
  ≥70 years                CC     19 (17.6)         1                     
  ( *n* =108)              CT     64 (59.3)         0.670 (0.319-1.407)   0.290
                           TT     25 (23.1)         0.643 (0.343-1.207)   0.169
  Gleason score, *n* (%)                                                  
  ≤7                       CC     26 (21.7)         1                     
  ( *n* =120)              CT     69 (57.5)         0.867 (0.457-1.644)   0.661
                           TT     25 (20.8)         0.787 (0.466-1.332)   0.373
  8                        CC     20 (27.8)         1                     
  ( *n* =72)               CT     36 (50.0)         1.042 (0.499-2.173)   0.913
                           TT     16 (22.2)         1.161 (0.631-2.136)   0.631
  ≥9                       CC     8 (16.7)          1                     
  ( *n* =48)               CT     30 (62.5)         0.667 (0.249-1.787)   0.420
                           TT     10 (20.8)         0.557 (0.244-1.272)   0.165
  PSA (ng/mL), *n* (%)                                                    
   20                      CC     29 (24.8)         1                     
  ( *n* =117)              CT     64 (54.7)         1.007 (0.535-1.897)   0.983
                           TT     24 (20.5)         0.947 (0.566-1.585)   0.836
  ≥20, 50                  CC     11 (18.3)         1                     
  ( *n* =60)               CT     33 (55.0)         0.573 (0.249-1.321)   0.191
                           TT     16 (26.7)         0.697 (0.334-1.451)   0.334
  ≥50                      CC     14 (22.2)         1                     
  ( *n* =63)               CT     38 (60.3)         1.061 (0.451-2.495)   0.893
                           TT     11 (17.5)         0.770 (0.394-1.504)   0.444
  Stage, *n* (%)                                                          
  T2                       CC     28 (24.5)         1                     
  ( *n* =114)              CT     63 (55.3)         1.014 (0.534-1.928)   0.965
                           TT     23 (20.2)         0.929 (0.552-1.563)   0.781
  T3                       CC     15 (18.7)         1                     
  ( *n* =80)               CT     45 (56.3)         0.625 (0.296-1.318)   0.217
                           TT     20 (25.0)         0.697 (0.366-1.326)   0.271
  T4                       CC     11 (23.9)         1                     
  ( *n* =46)               CT     27 (58.7)         1.146 (0.435-3.018)   0.783
                           TT     8 (17.4)          0.851 (0.402-1.805)   0.675
  Metastasis, *n* (%)                                                     
  non-metastasis           CC     42 (21.4)         1                     
  ( *n* =196)              CT     108 (55.1)        0.761 (0.447-1.296)   0.314
                           TT     46 (23.5)         0.813 (0.520-1.271)   0.363
  metastasis               CC     12 (27.3)         1                     
  ( *n* =44)               CT     27 (61.3)         2.000 (0.670-5.972)   0.214
                           TT     5 (11.4)          0.929 (0.447-1.930)   0.843

OR: odds ratio; CI: confidence interval

Discussion
==========

In this study, we investigated the role of the genetic variation of *PSCA* rs2294008 in prostate cancer susceptibility. It was found that the variation of *PSCA* rs2294008 was not associated with prostate cancer.

*PSCA* was initially identified and isolated as a tumor antigen highly expressed in prostate cancer^\[[@R8]\]^. *PSCA* plays a role in signal transduction and cell-growth regulation^\[[@R11]\]^. *PSCA* is highly expressed in the prostate, bladder, and pancreatic carcinomas, but downregulated in gastric, esophageal, and head-and-neck carcinomas^\[[@R9],\ [@R12]--\ [@R14]\]^. Therefore, the role of *PSCA* in carcinogenesis remains still controversial.

The genetic polymorphism of *PSCA* (rs2294008) is associated with the increased incidence of gastric cancer in the Korean population^\[[@R15]\]^. Song *et al.* ^\[[@R15]\]^ have reported that the CT and TT genotypes are associated with a significantly increased risk of gastric cancer (OR= 1.5 and 1.71, respectively) compared to the CC genotype. However, Lu *et al.* ^\[[@R16]\]^ have demonstrated that rs2294008 variant genotypes (CC/CT) are not associated with increased risk of gastric cancer in the Chinese population. Thus, the genetic polymorphism of *PSCA* and its association with gastric cancer risk may differ among races. Similarly, in bladder cancer, Yates *et al.* ^\[[@R17]\]^ have suggested that genetic polymorphism on 8q24 is associated with an increased risk of bladder cancer, but not associated with disease aggressiveness. In addition, Fu *et al.* ^\[[@R18]\]^ have indicated that rs2294008 is important for bladder cancer susceptibility.

Analysis of 12 genotypes for *PSCA* revealed that the rs1045531 is significantly associated with an increased risk of prostate cancer and that CCCAGGTACGG and CGA haplotype carriers have a significant association with risk of prostate cancer^\[[@R10]\]^. To the best of our knowledge, there is only one study by Joung *et al.* \[([@R10])\] on the association between prostate cancer risk and genetic polymorphisms of *PSCA* .

There are some limitations in the present study. The sample size of our study is relatively small for identifying genetic susceptibility. We investigated only the *PSCA* gene rs2294008 among various *PSCA* genetic polymorphisms. Further large cohort studies are needed to confirm our results. Also, large cohort studies on genetic variants of *PSCA* in Western countries are required to identify the association between the risk of prostate cancer and SNP.

In conclusion, the genetic polymorphism of *PSCA* rs2294008 was not associated with the risk of prostate cancer. Our results suggest that rs2294008 may not play a role in the pathogenesis of prostate cancer. However, since *PSCA* as a transmembrane protein is associated with prostate cancer, additional studies on polymorphisms in the *PSCA* gene in addition to rs2294008 are needed to confirm the association between *PSCA* SNP and prostate cancer.
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